No one is saying the DEP® Irinotecan interim results aren't promising but let's be honest, we heard all the same hype back in 2021 when the DEP® Cabazitaxel interim results were released - Starpharma have as of yet been unable to capitalise on those DEP® Cabazitaxel interim results and deliver a license deal two years down the track even after admitting that "several potential pharmaceutical companies / partners" were looking at the results and even possibly now extended DEP® Cabazitaxel phase 2 data behind a similar NDA ? These are open label trials folks .... anyone under an NDA would have seen extensive data in comparison to what the market has ....
My question remains - Why aren't these big pharma companies snapping up one of our DEP® drugs through a license deal if all of the DEP® results from the multiple in house phase 2 trials are as good as many on here want you to believe ? Perhaps once the full results / data are actually perused by these big pharma companies under an NDA they don't stack up as a whole as purported through the cherry picked case studies in various SPL ASX announcements over the years ?
"Data from this cohort of prostate cancer patients is being presented in confidential commercial discussions with several potential pharmaceutical companies / partners."
Bring on the Viraleze UK after market study results I say
GLTAH
Ann: DEP irinotecan clinical data presented at AACR meeting, page-10
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
